论文部分内容阅读
３７所医院对急性心肌梗塞患者５２８例，随机分为尿激酶组（２７２例）和去纤酶组（２５６例）均为静脉法给药，尿激酶组并辅以阿司匹林和肝素，对比两组溶栓疗效。尿激酶组与去纤酶组比较：血管再通率分别为５８．１％对４０．６％（Ｐ＜０．００１）；４周病死率分别为８．１％对１７．６％（Ｐ＜０．００５）；出血并发症分别为１１．０％对２７．０％（Ｐ＜０．００１）。说明尿激酶组疗效明显优于去纤酶组，且出血并发症较少。血管再通者较血管未通者严重并发症和梗塞延展明显减少，明显降低急性期病死率。
In the 37 hospitals, 528 patients with acute myocardial infarction were randomly divided into two groups: urokinase group (272 cases) and defibrase group (256 cases), all of which were intravenously administered with urokinase supplemented with aspirin and heparin. Thrombolytic effect. The rates of recanalization were 58.1% vs 40.6%, respectively (P <0.001) for urokinase and defibrase groups; the 4-week mortality rates were 8.1% vs 17.6% (P <0.005). Hemorrhagic complications were 11.0% vs 27.0% (P <0.001), respectively. The efficacy of urokinase group was significantly better than that of defibrase group with less bleeding complication. Severe vascular recanalization than those with serious complications and infarct extension was significantly reduced, significantly reducing mortality in acute phase.